GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (FRA:3XI) » Definitions » Debt-to-Revenue

Biomind Labs (FRA:3XI) Debt-to-Revenue : N/A (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Biomind Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.80 Mil. Biomind Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. Biomind Labs's annualized Revenue for the quarter that ended in Sep. 2024 was €0.00 Mil.


Biomind Labs Debt-to-Revenue Historical Data

The historical data trend for Biomind Labs's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Debt-to-Revenue Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A N/A

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Biomind Labs's Debt-to-Revenue

For the Biotechnology subindustry, Biomind Labs's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomind Labs's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biomind Labs's Debt-to-Revenue falls into.



Biomind Labs Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Biomind Labs's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.678 + 0) / N/A
=N/A

Biomind Labs's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Biomind Labs Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biomind Labs's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs Headlines

No Headlines